Skip to main content
Oncotarget logoLink to Oncotarget
. 2017 Oct 31;8(63):106976–106988. doi: 10.18632/oncotarget.22202

Whole exome sequencing identifies novel mutation in eight Chinese children with isolated tetralogy of Fallot

Lin Liu 1,*, Hong-Dan Wang 2,*, Cun-Ying Cui 1, Yun-Yun Qin 1, Tai-Bing Fan 3, Bang-Tian Peng 3, Lian-Zhong Zhang 1, Cheng-Zeng Wang 4
PMCID: PMC5739789  PMID: 29291004

Abstract

Background

Tetralogy of Fallot is the most common cyanotic congenital heart disease. However, its pathogenesis remains to be clarified. The purpose of this study was to identify the genetic variants in Tetralogy of Fallot by whole exome sequencing.

Methods

Whole exome sequencing was performed among eight small families with Tetralogy of Fallot. Differential single nucleotide polymorphisms and small InDels were found by alignment within families and between families and then were verified by Sanger sequencing. Tetralogy of Fallot-related genes were determined by analysis using Gene Ontology /pathway, Online Mendelian Inheritance in Man, PubMed and other databases.

Results

A total of sixteen differential single nucleotide polymorphisms loci and eight differential small InDels were discovered. The sixteen differential single nucleotide polymorphisms loci were located on Chr 1, 2, 4, 5, 11, 12, 15, 22 and X. Among the sixteen single nucleotide polymorphisms loci, six has not been reported. The eight differential small InDels were located on Chr 2, 4, 9, 12, 17, 19 and X, whereas of the eight differential small InDels, two has not been reported. Analysis using Gene Ontology /pathway, Online Mendelian Inheritance in Man, PubMed and other databases revealed that PEX5, NACA, ATXN2, CELA1, PCDHB4 and CTBP1 were associated with Tetralogy of Fallot.

Conclusions

Our findings identify PEX5, NACA, ATXN2, CELA1, PCDHB4 and CTBP1 mutations as underlying genetic causes of isolated tetralogy of Fallot.

Keywords: tetralogy of Fallot, congenital heart disease, whole exome sequencing

INTRODUCTION

Tetralogy of Fallot (TOF) is the most common cyanotic congenital heart disease (CHD) with an incidence rate of 1/3600 in live births and 10% in CHD [1]. TOF is characterised by cardiac outflow tract malformation caused by non-uniform separation between truncus arteriosus and bulbus arteriosus during embryo stage. TOF pathological features include ventricular septal defect, aortic overriding, right ventricular outflow tract stenosis or pulmonary artery stenosis and right ventricular hypertrophy. In neonatal period, children with TOF may manifest oxygen deficiency, pneumonia, intractable congestive heart failure and other complications with high early mortality. Despite TOF treatment in children, some complications will still occur because of poor prognosis. TOF brings heavy burden to the family and society. Therefore, to investigate TOF etiology, possible pathogenesis and risk factors for prenatal diagnosis and counselling and prognostic evaluation is of great significance.

Heart development is a complex and orderly process including cardiac tube formation, loop formation, intracardiac separation and vascular connection. Heart development is related to many genes, which express and interact in different spaces and at different times to form a precise regulatory mechanism. Abnormal expression occurring in any of these genes is likely to affect heart development, leading to heart malformation. For TOF, embryonic developmental mechanism is nearly definite. However, the molecular pathogenesis remains to be clarified. TOF is associated with gene mutation [2]. TOF-related genes include NKX2-5 [3], GATA4 [3, 4], and JAG-1 [5, 6]. Approximately 15% of TOF are from 22q11 microdeletion syndrome [7] caused by chromosome 22 long arm 1 zone 1 subzone deletion and manifest extracardiac abnormalities, such as abnormal face, thymic hypoplasia, cleft palate and hypocalcemia. In addition, TOF is also related to chromosomal aneuploidy, and approximately 3% of TOF is from 21-trisomy syndrome [8]. However, the pathogenesis of isolated TOF is still to be elucidated.

Whole exome sequencing (WES) is suitable to high-throughput sequencing for all genomic exon regions. Human exome accounting for approximately 1%–2% of genome contains important information of protein synthesis, which directly reflects gene function. In most diseases, related mutations are located in the exome region. WES may be used to find pathogenic gene and predisposing gene in complex diseases, monogenic diseases and cancer because it can investigate protein encoding information in several individuals; its data are also accurate [9]. The aim of this study was to find TOF-related pathogenic genes through WES technology performed among eight small families with TOF, providing a basis for studying TOF pathogenesis.

RESULTS

Clinical features

All the eight TOF children manifested cyanosis and rough systolic-ejection murmurs at the left sternal border between the second and fourth ribs. Echocardiography showed right ventricular enlargement, right ventricular anterior wall thickening, right ventricular outflow tract and pulmonary artery stenosis, ventricular septal defect and aortic overriding (Figure 1). The echocardiographic results of eight TOF children in the right ventricle, right ventricular anterior wall, right ventricular outflow tract, main pulmonary artery, left pulmonary artery, right pulmonary artery, ventricular septal defect and left ventricular ejection fraction (Table 1). The eight TOF children displayed no other malformations, and their parents showed no abnormalities.

Figure 1.

Figure 1

(A) Ventricular septal defect and aortic overriding shown in the left ventricular long-axis view of transthoracic echocardiography. (B) Pulmonary artery stenosis shown in the aorta short-axis view of transthoracic echocardiography.

LA: left atrium; LV: left ventricle; AO: aorta; VSD: ventricular septal defect; RA: right atrium; RV: right ventricle; PA: pulmonary artery; RVOT: right ventricular outflow tract.

Table 1. Results of echocardiogram in the 8 children with tetralogy of Fallot.

ID Gender Age RV (mm) RVAW (mm) RVOT (mm) MPA (mm) LPA (mm) RPA (mm) VSD (mm) LVEF (%)
1 female 3months 8.0 5.0 5.4 5.6 4.3 4.8 9.5 73
2 male 8months27days 12.0 6.0 5.7 5.3 4.3 5.3 10.2 68
3 male 1years11months 13.9 6.8 7.2 10.5 6.6 6.7 13.5 72
4 female 2months24days 11.8 4.1 6.0 15.3 9.3 7.7 11.5 57
5 female 6months 11.1 6.1 9.0 11.8 7.6 7.6 12.9 67
6 male 8months2days 13.0 6.3 7.0 6.4 4.2 4.4 13.5 72
7 female 11months26days 13.4 5.9 5.8 12.4 6.7 7.1 13.1 69
8 male 6months11days 10.3 5.0 6.1 9.0 4.3 5.7 13.2 74

RV: right ventricle; RVAW: right ventricular anterior wall; RVOT: Right ventricular outflow tract; MPA: main pulmonary artery; LPA: left pulmonary artery; RPA: right pulmonary artery; VSD: ventricular septal defect; LVEF: left ventricular ejection fraction.

Mutation detection

A total of sixteen differential single nucleotide polymorphisms (SNPs) loci and eight differentially small InDels were discovered by sequencing all exons in the eight small families and alignment of SNPs and small InDels within families and between families (Table 2 and Table 3).

Table 2. SNPs identified by whole exome sequencing.

Chr Position ID Ref Alt Mutation Symbol Amino acids SIFT PolyPhen
chr12 56717682 rs745387506 T G missense NACA H/P - unknown(0)
chr5 141123595 - T A missense PCDHB4 S/T tolerated (1) benign(0)
chr12 7190555 - G C missense PEX5 A/P tolerated (0.22) benign(0.067)
chr2 240042663 - C T missense PRR21 R/H tolerated (0.56) unknown(0)
chr4 1237208 - A T stop_gained CTBP1 C/* - -
chrX 37010556 rs61999275 G C missense FAM47C A/P tolerated(1) benign(0)
chr1 26282352 rs6667693 C A missense UBXN11 G/C tolerated (0.05) unknown(0)
chr1 86368686 rs75376884 T C missense ODF2L M/V tolerated (0.14) benign(0.001)
chr4 87614868 - G A missense DSPP D/N - unknown(0)
chr4 87614877 rs150132251 A G missense DSPP N/D - unknown(0)
chr4 88008301 rs117078377 G A missense PKD2 A/T tolerated(0.3) benign(0.395)
chr11 71527593 rs199903176 A G missense KRTAP5-7 Y/C tolerated (0.22) unknown(0)
chr12 51346625 rs117443541 T G missense CELA1 Y/S tolerated(0.13) benign(0.045)
chr15 88856792 rs12899191 A G missense ACAN T/A tolerated(0.56) benign(0.084)
chrX 104250509 rs9697856 T G missense ESX1 T/P tolerated (0.54) unknown(0)
chr22 11068057 - A T missense BAGE5 R/W tolerated (0.12) damaging(0.675)

Chr: chromosome; Ref: reference sequence base; Alt: alternative base identified; SIFT: sorting intolerant from tolerant.

Table 3. Small InDels identified by whole exome sequencing.

Chr Position ID Ref Alt Mutation Symbol Amino acids SIFT PolyPhen
chr2 104856098 rs775150602 AGCC A inframe_deletion POU3F3 A/- - -
chr12 111598972 rs769170503 C CTGT inframe_insertion ATXN2 Q/QQ - -
chr4 13632182 . CT C splice_acceptor_variant&non_coding_transcript_variant - -
chr9 136327352 . ACCCCCTC A TF_binding_site_variant&TFBS_ablation GPSM1 - - -
chr17 75616380 rs371699907 CAGG C inframe_deletion MYO15B QE/Q - -
chr19 9251064 rs201985790 CT C frameshift_variant OR7E24 F/X - -
chr19 51694076 rs10689461 C CAG splice_acceptor_variant&non_coding_transcript_variant SPACA6P - - -
chrX 19345745 rs776856509 TC TCC, T frameshift_variant PDHA1 S/X - -

Ten of the sixteen differential SNPs were reported, namely, Chr1 (rs6667693, UBXN11), Chr1 (rs75376884, ODF2L), Chr4 (rs150132251, DSPP), Chr4 (rs117078377, PKD2), Chr11 (rs199903176, KRTAP5-7), Chr12 (rs745387506, NACA), Chr12 (rs117443541, CELA1), Chr15 (rs12899191, ACAN), ChrX (rs61999275, FAM47C) and ChrX rs9697856, ESX1). Six of the 16 differential SNPs were not reported, namely, Chr 2 (PRR21), Chr 4 (CTBP1), Chr 4 (DSPP), Chr 5 (PCDHB4), Chr12 (PEX5) and Chr22 (BAGE5).

Six of the eight differentially small InDels were reported, namely, Chr2 (rs775150602, POU3F3), Chr12 (rs769170503, ATXN2), Chr17 (rs371699907, MYO15B), Chr19 (rs201985790, OR7E24), Chr19 (rs10689461, SPACA6P) and ChrX (rs776856509, PDHA1). Two of the eight differentially small InDels were not reported, namely, Chr4 (position: 13632182) and Chr9 (GPSM1).

SNPs and small InDel-related Online Mendelian Inheritance in Man (OMIM) genes and clinical phenotypes are shown in Table 4.

Table 4. SNPs- and small InDels-related OMIM genes and clinical phenotypes.

Gene Chromosome OMIM Gene description Function
NACA Chr12 601234 gene encodes a protein that associates with BTF3 to form NAC skeletal development
PCDHB4 Chr5 606330 a member of the protocadherin beta gene cluster cell-cell neural connections
PEX5 Chr12 600414 peroxisomal biogenesis factor 5 Peroxisome biogenesis disorder 2A, 2B; Rhizomelic chondrodysplasia punctata, type 5
PRR21 Chr2 - - -
CTBP1 Chr4 602618 gene encodes a protein that binds to the C-terminus of adenovirus E1A proteins transcriptional repressor and cellular proliferation
FAM47C ChrX - - -
UBXN11 Chr1 609151 a protein with a divergent C-terminal UBX domain affect the actin cytoskeleton and alter cell shape
ODF2L Chr1 - - -
DSPP Chr4 125485 a member of the small integrin-binding ligand N-linked glycoprotein family of proteins Deafness, autosomal dominant 39, with dentinogenesis; Dentin dysplasia, type II; Dentinogenesis imperfecta, Shields type II, III
PKD2 Chr4 173910 a member of the polycystin protein family Polycystic kidney disease 2
KRTAP5-7 Chr11 - - -
CELA1 Chr12 130120 Elastases form a subfamily of serine proteases that hydrolyze many proteins in addition to elastin evolutionarily silenced in pancreatic acinar cells
ACAN Chr15 155760 a member of the aggrecan/versican proteoglycan family Osteochondritis dissecans, short stature, and early-onset osteoarthritis; Spondyloepimetaphyseal dysplasia, aggrecan type; Spondyloepiphyseal dysplasia, Kimberley type
ESX1 ChrX 300154 gene encodes a dual-function 65 kDa protein that undergoes proteolytic cleavage to produce a 45 kDa N-terminal fragment with a paired-like homeodomain and a 20 kDa C-terminal fragment with a proline-rich domain placental development and spermatogenesis
BAGE5 Chr22 - - -
POU3F3 Chr2 602480 a member of the class III POU family of transcription factors expressed in the central nervous system
ATXN2 Chr12 601517 gene belongs to a group of genes that is associated with microsatellite-expansion diseases, a class of neurological and neuromuscular disorders caused by expansion of short stretches of repetitive DNA Spinocerebellar ataxia 2; susceptibility to Amyotrophic lateral sclerosis; susceptibility to Parkinson disease, late-onset
GPSM1 Chr9 609491 gene encodes a receptor-independent activator of G protein signaling, influence the basal activity of G-protein signaling systems
MYO15B Chr17 - - -
OR7E24 Chr19 - - -
SPACA6P Chr19 - - -
PDHA1 ChrX 300502 a nuclear-encoded mitochondrial multienzyme complex that catalyzes the overall conversion of pyruvate to acetyl-CoA and CO(2), and provides the primary link between glycolysis and the tricarboxylic acid cycle Pyruvate dehydrogenase E1-alpha deficiency

We discovered fourteen SNPs- and Small InDels-related OMIM genes, including: NACA, PCDHB4, PEX5, CTBP1, UBXN11, DSPP, PKD2, CELA1, ACAN, ESX1, POU3F3, ATXN2, GPSM1, PDHA1. PEX5 (OMIM:600414) is associated with Peroxisome biogenesis disorder 2A, 2B. NACA (OMIM:601234) is associated with skeletal development. ATXN2 (OMIM:601517) is associated with Spinocerebellar ataxia 2, susceptibility to Amyotrophic lateral sclerosis, susceptibility to Parkinson disease and late-onset. CELA1 (OMIM:130120) is associated with evolutionarily silenced in pancreatic acinar cells. PCDHB4 (OMIM:606330) cell-cell neural connections is associated with CTBP1(OMIM:602618) transcriptional repressor and cellular proliferation.

Results verified by Sanger sequencing

We designed twenty-four pairs of primers to verify sixteen differential SNPs loci and eight differentially small InDels. The results of Sanger sequencing are consistent with that of WES (Figure 2).

Figure 2. Diagram of the Sanger sequencing for two mutations.

Figure 2

(A) chr4:13632182 (CT→C). (B) chr1:86368686 (T→C).

The verification of sixteen differential SNPs sites included NACA (rs745387506, T>G), FAM47C (rs61999275, G>C), UBXN11 (rs6667693, C>A), ODF2L (rs75376884, T>C), DSPP (rs150132251, A>G), PKD2 (rs117078377, G>A), KRTAP5-7 (rs199903176, A>G), CELA1 (rs117443541, T>G), ACAN (rs12899191, A>G), ESX1 (rs9697856, T>G), PCDHB4 (chr5, 141123595, T>G), PEX5 (chr12, 7190555, G>C), PRR21 (chr2, 240042663, C>T), CTBP1 (chr4, 1237208, A>T), DSPP (chr4, 87614868, G>A) and BAGE5 (chr22, 11068057, A>T) were investigated.

The verification of eight differentially small InDels sites included AGCC (rs775150602, AGCC>A), ATXN2 (rs769170503, C>CTGT), MYO15B (rs371699907, CAGG>C), OR7E24 (rs201985790, CT>C), SPACA6P (rs10689461, C>CAG), PDHA1 (rs776856509, TC>TCCT), GPSM1 (chr9, 136327352, ACCCCCTC>A), and (chr4, 13632182, CT>T) were investigated.

Gene ontology (GO)/pathway analysis

GO analysis indicated the percentages of 22 genes enriched in GO term (Figure 3). Growth was related to CHD, and it was associated with some genes including PEX5, NACA, ATXN2 and CELA1 (Table 5). PEX5, ATXN2 and CELA1 are responsible for multicellular organism growth (GO:0035264). PEX5, ATXN2, NACA and CELA1 are responsible for developmental growth (GO:0048589). PEX5, ATXN2 and NACA are responsible for regulation of developmental growth (GO:0048638) and growth regulation (GO:0040008). PEX5 and ATXN2 are responsible for regulation of multicellular organism growth (GO:0040014). PEX5 and NACA are responsible for positive regulation of developmental growth (GO:0048639) and positive growth regulation (GO:0045927). PEX5 is responsible for positive regulation of multicellular organism growth (GO:0040018). ATXN2 is responsible for negative regulation of multicellular organism growth (GO:0040015), epidermal growth-factor receptor binding (GO:0005154), negative regulation of developmental growth (GO:0048640), growth-factor receptor binding (GO:0070851) and negative growth regulation (GO:0045926).

Figure 3. GO analysis of 22 genes.

Figure 3

Table 5. Genes involved by growth and possibly associated with CHD in GO term.

Gene Term Database ID
PEX5:5830|ATXN2:6311|CELA1:1990 multicellular organism growth Biological Process GO:0035264
PEX5:5830|ATXN2:6311|NACA:4666|CELA1:1990 developmental growth Biological Process GO:0048589
PEX5:5830|ATXN2:6311|NACA:4666 regulation of developmental growth Biological Process GO:0048638
PEX5:5830|ATXN2:6311 regulation of multicellular organism growth Biological Process GO:0040014
PEX5:5830|NACA:4666 positive regulation of developmental growth Biological Process GO:0048639
PEX5:5830|ATXN2:6311|NACA:4666|CELA1:1990 growth Biological Process GO:0040007
PEX5:5830|NACA:4666 positive regulation of growth Biological Process GO:0045927
PEX5:5830|ATXN2:6311|NACA:4666 regulation of growth Biological Process GO:0040008
PEX5:5830 positive regulation of multicellular organism growth Biological Process GO:0040018
ATXN2:6311 negative regulation of multicellular organism growth Biological Process GO:0040015
ATXN2:6311 epidermal growth factor receptor binding Molecular Function GO:0005154
ATXN2:6311 negative regulation of developmental growth Biological Process GO:0048640
ATXN2:6311 growth factor receptor binding Molecular Function GO:0070851
ATXN2:6311 negative regulation of growth Biological Process GO:0045926

Repression of Wnt target genes and Notch signalling were related to CHD, and was associated with PCDHB4 and CTBP1 genes (Table 6). Pathway analysis showed that twenty-two genes were enriched at the top fifty of pathway term (Figure 4). Genes involved in the Wnt (CTBP1 and PCDHB4) and Notch (CTBP1) signalling are important for pathway analysis in cardiac development. The mutation sites in the six genes were as follows: PEX5 (A60P), NACA (H1283P), ATXN2 (Q21QQ), CELA1 (Y5S), PCDHB4 (S533T) and CTBP1 (C35*). The transcript number of ATXN2 (Q21QQ) is ENST00000608853.5, and the transcript number of CTBP1 (C35*) is ENST00000629223.1.

Table 6. Genes involved by pathway and possibly associated with CHD.

Gene Term Database ID
CTBP1:1487 repression of WNT target genes Reactome REACT_264567
CTBP1:1487 AXIN mutants destabilize the destruction complex, activating WNT signaling Reactome REACT_264496
CTBP1:1487 deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Reactome REACT_264286
CTBP1:1487 WNT signaling pathway KEGG PATHWAY hsa04310
CTBP1:1487 TCF dependent signaling in response to WNT Reactome REACT_264596
CTBP1:1487 RNF mutants show enhanced WNT signaling and proliferation Reactome REACT_264378
CTBP1:1487 Signaling by WNT Reactome REACT_11045
CTBP1:1487 Notch signaling pathway KEGG PATHWAY hsa04330
PCDHB4:56131|CTBP1:1487 WNT signaling pathway PANTHER P00057

Figure 4. Pathway analysis of 22 genes.

Figure 4

Variant analysis

By alignment of protein sequences of PEX5, NACA, ATXN2, CELA1, PCDHB4 and CTBP1, S5333T of PCDHB4 was highly evolutionarily conserved in diverse species including Homo sapiens, Pan paniscus, Pongo abelii and gorilla (Figure 5a). In addition, Y5S of CELA1 was highly evolutionarily conserved in diverse species including H. sapiens, gorilla, Saimiri boliviensis, Papio anubis, Peromyscus maniculatus, Tapirus bairdii, Eptesicus fuscus and Sus scrofa (Figure 5b). The highly evolutionarily conserved protein sequences were not found in PEX5, NACA, ATXN2 and CTBP1 in other species.

Figure 5.

Figure 5

(A) Alignment of multiple PCDHB4 protein sequences in different species reveals that the S533T amino acid is located in the highly conserved amino acid region in different species. (B) Alignment of multiple CELA1 protein sequences in different species reveals that the Y33T amino acid is located in the highly conserved amino acid region in different species.

DISCUSSION

TOF as the most common cyanotic CHD is characterised by right ventricular outflow tract obstruction, pulmonary stenosis, ventricular septal defect and aortic overriding caused by non-uniform separation between the truncus arteriosus and bulbus arteriosus at embryo stage. Currently, surgical repair is usually performed in the first month after birth to relieve the stenosis of the right outflow tract and close ventricular septal defect, enabling an exclusive ejection of oxygenated blood via the left ventricle. Cumulative survival and event-free survival were 72% and 25%, respectively, 40 years after follow-up [12].

TOF etiology still needs to be completely clarified because of TOF complexity attributed by both genetic and nongenetic effectors. Next-generation sequencing technology, such as WES with rapid, high throughput and cost-effective features, can meet the requirements for medical studies. WES has been used to obtain information about genetic alterations and potential predispositions possibly associated with TOF occurrence.

Eight small families were tested through WES, and differential SNP loci and InDels were found. From the comparison within each family and among the families, sixteen differential SNPs loci and eight differential Small InDels were screened out. Corresponding genes exist in the database, wherein ten of the sixteen differential SNPs have been reported and six of the sixteen differential SNPs have not been reported. Among the eight Small InDels, seven small Indels have corresponding genes in the database and one Small InDels does not have. Six of the eight differential Small InDels have been reported, whereas two of them have not. Among them, no gene in the database corresponds to the mutation of chr4, position: 13632182. It might be located among the genes or among noncoding regions, and the function requires further study. Go/Pathway analysis of the sixteen differential SNPs loci and eight differential Small InDels were conducted and PEX5, NACA, ATXN2, CELA1, PCDHB4 and CTBP1 were finally screened out and were associated with TOF.

Similar to some genes found to be related to TOF by detection of chromosome karyotype, gene copy number variation and de novo mutation (Table 7), Greenway et al. [13] found four genes (PRKAB2, CHD1L, BCL9 and GJA5) with the highest expression in the right ventricular outflow tract, which is malformed in TOF. Bittel et al. [14] included both idiopathic TOF patients and three patients, which harbour the syndromic 22q11.2 deletion. The expression of the genes A2BP1, VEGF, NPPA and NPPB located in the 22q11.2 region was half-reduced among syndromic patients as expected, whereas none of these genes was differentially expressed in any of the idiopathic TOF subjects. Notch pathway was also suppressed in patients with 22q11.2 deletions. Sharma et al. [15, 16] found that TOF expression of the majority of the genes associated with Wnt and Notch signalling pathways was significantly reduced. Their results also confirmed an upregulated expression of VEGF and proteins of the extracellular matrix reported in previous studies. Feiner et al. [17] found a novel locus at 1q32.2 in two unrelated TOF who displayed loss of copy number variations overlapping the PLXNA2 gene. Knockout mice deficient for PLXNA2 display CHD including TOF [18]. Amarillo et al. [19] found a 3.76 Mb de novo contiguous gain of 9q34.2-q34.3 by chromosome microarray analysis and then also confirmed it by karyotype analysis and fluorescence in situ hybridization. This duplicated interval disrupted retinoid X receptor alpha (OMIM #180245) at intron 1. To our knowledge, PEX5, PCDHB4, CTBP1, NACA, ATXN2 and CELA1 are novel SNPs associated with TOF, which have not been reported.

Table 7. Summary of genes with a potential relevance to TOF.

References Subjects Platform Genes Conclusions
Steven C et al (2009) 114 TOF Trios 398 TOF Affymetrix Human Genome Wide SNP Array 6.0 PRKAB2, CHDIL, BCL9, GJA5 potential TOF candidate gene
Douglas C Bittel et al (2011) 19 TOF Applied Microarrays Inc. CodeLink Human Whole Genome Bioarray A2BP1, VEGF, NPPA, NPPB, potential relevance for TOF
Amy Rodemoyer et al (2011) 16 TOF Affymetrix Human Exon 1.0 ST v2 NEFH, SST, TF, KRT6A, KRT7, NTRK2, MYL2, PPBP, NRGN, APOC3 dysregulated network in TOF
Goodship et al (2012) 362 TOF SEQUENOM MALDI-TOF PTPN11 risk allele for TOF
Candice K et al (2012) 433 TOF Affymetrix Genome-Wide Human SNP Array 6.0 GJA5, PLXNA2 potential TOF candidate gene
Rachel Soemedi et al (2012) 283 TOF Trios Illumina 660W SNP Array 6.0 GJA5, HAND2, EDIL3, CNOT6 potential TOF candidate gene
Heather J.Cordell et al (2013) 798 TOF Illumina 600W QUAD array PTPN11, GPC5, NRP1 risk allele for TOF
Marcel Grunert et al (2014) 22 TOF NimbleGen sequence capture 365K array Genome Sequencer FLX Illumina Genome Analyzer deleterious SNPs in BARX1, BCCIP, DAG1, EDN1, FANCL, FANCM, FMR1, FOXK1, HCN2, MYOM2, PEX6, ROCK1, TCEB3, TP53BP2, TTN, WBSCR16 imbalance of functional networks in TOF
Tan ZP et al (2015) 1 TOF Illumina Hiseq2000 SCN5A a possible cause of TOF
LaHaye S et al (2016) 2 TOF Illumina Hiseq2000 MYBPC3, SOS1 uncertain significance

Our study aimed to identify other monogenic causes of TOF. GO analysis indicated that PEX5 was related to multicellular organism growth (GO:0035264), developmental growth (GO:0048589), regulation of developmental growth (GO:0048638), regulation of multicellular organism growth (GO:0040014), positive regulation of developmental growth (GO:0048639), positive regulation of growth (GO:0045927), growth (GO:0040007) and positive regulation of multicellular organism growth. In the 26 cases with TOF, Grunert M et al. [20] found deleterious SNPs in 16 genes, including BARX1, BCCIP, DAG1, EDN1, FANCL, FANCM, FMR1, FOXK1, HCN2, MYOM2, PEX6, ROCK1, TCEB3, TP53BP2, TTN and WBSCR16 which resulted in the imbalance of function networks in TOF. Huffnagel IC et al.[21] found that two of the 21 genetically proven Rhizomelic chondrodysplasia punctata patients suffered from TOF and showed PEX7 mutations. Plasmalogens were not detected in cardiac tissue of PEX7 knock-out mice, which is a model for RCDP type 1. The above-mentioned PEX5, PEX6 and PEX7 are all PEX family gene named Peroxins (PEXs) which are proteins essential for the assembly of functional peroxisomes. Therefore, PEX5 might participate in TOF growth and development process. PCDHB4 is located on Chr5q31.3. This gene is a member of the protocadherin beta gene cluster and is one of the three related and tandemly linked gene clusters at chromosome 5. Their specific functions are unknown but they most likely play a critical role in the establishment and function of specific cell–cell neural connections. Alazami AM et al. [22] performed WES on 143 multiplex consanguineous families, in which known disease genes had been excluded by autozygosity mapping. Patients, whose clinical phenotype is featured by global developmental delay and brain atrophy, have mutation in PCDHB4 (NM_021908:c.489T>G:p.Y163X) based on the candidate gene analysis, and the function of which participated in the growth and development process. Base on our research, Go analysis indicated that PCDHB4 (P00057) was related to WNT signaling pathway. Thus, PCDHB4 (P00057) may be a potential TOF candidate gene. NACA is located on Chr12q13.3. The protein encoded by NACA is associated with basic transcription factor 3, which forms the nascent polypeptide-associated complex. In this study, GO analysis indicated that NACA was related to positive regulation of developmental growth (GO:0048639) and positive regulation of growth (GO:0045927). Thus, NACA may be a potential TOF candidate gene. CELA1 is located on Chr12q13.13. This gene forms a subfamily of serine proteases that hydrolyze many proteins in addition to elastin. Humans possess six elastase genes, which encode the structurally similar elastases 1, 2, 2A, 2B, 3A and 3B. Unlike other elastases, pancreatic elastase 1 is not expressed in the pancreas. GO analysis indicated that CELA1 was related to multicellular organism growth (GO:0035264), developmental growth (GO:0048589) and growth (GO:0040007). Thus, CELA1 may have a potential relevance to TOF. ATXN2 is located on Chr12q24.12 with a transcript number of ENST00000608853.5. This gene belongs to a group of genes that are associated with microsatellite-expansion diseases, a class of neurological and neuromuscular disorders caused by expansion of short stretches of repetitive deoxyribonucleic acid (DNA). Genome-wide association studies indicate that loss-of-function mutations in this gene may be associated with susceptibility to type I diabetes, obesity and hypertension. Alternative splicing leads to multiple transcript variants. GO analysis indicated that ATXN2 was related to negative regulation of multicellular organism growth (GO:0040015), epidermal growth-factor receptor binding (GO:005154), negative regulation of developmental growth (GO:0048640), growth-factor receptor binding (GO:0070851) and negative regulation of growth (GO:0045926). Thus, ATXN2 may have a potential relevance to TOF. CTBP1 is located on Chr4p16.12 with a transcript number of ENST00000629223.1. This gene encodes a protein that binds to the C-terminus of adenovirus E1A proteins. This phosphoprotein is a transcriptional repressor and may play a role in cellular proliferation. This protein and the product of a second closely related gene, CTBP1, can dimerise. Both proteins can also interact with a polycomb group protein complex, which participates in regulation of gene expression during development. Alternative splicing of transcripts from this gene results in multiple transcript variants. GO analysis indicated that CTBP1 was related to Wnt signalling pathway and Notch signalling pathway. Thus, CTBP1 may be a potential TOF candidate gene.

This study has some limitations, and the sample size is small. In the future, the number of samples will be further increased and an in-depth research will be conducted. The identified mutation sites have not been verified based on large TOF sample (n>50). Thus, whether the identified mutation sites may occur in a large group of TOF people has not been confirmed. Moreover, further study is necessary to verify relevant function genes and accordingly illustrate the pathogenesis of TOF.

In summary, TOF pathogenesis is complex because TOF is associated with more than one genetic variant. Eight small families were observed through WES and found that TOF-related genes were PEX5, NACA, ATXN2, CELA1, PCDHB4 and CTBP1, whose potential function might participate in TOF growth and development process. Although none of the three variants were predicted to be highly influential, they are in genes belonging to networks involved in relevant developmental pathways. Further study on the potential developmental mechanisms will be conducted based on these results.

MATERIALS AND METHODS

Subjects

A total of eight small families whose Chinese children received surgical TOF treatment at the Children’s Heart Center of Henan Provincial People’s Hospital between January 2016 and June 2016 were enrolled in this study. The eight children ageing 3–11 months included four male babies and four female babies. All manifested isolated TOF. Their parents were normal. All the eight children were diagnosed with TOF by echocardiogram, clinical symptoms and signs and intraoperative findings.

Methods

DNA extraction

In each member of the eight small families including 24 individuals, 600 μl peripheral blood was collected to extract genomic DNA using genomic DNA Extraction Kit (Qiage, Germany). The remaining blood samples were stored at −80°C.

WES and mutation screening

WES and subsequent variant annotation were performed on genomic DNA derived from the eight TOF children and their parents. Paired-end libraries were prepared according to the manufacturer’s protocols (Agilent). Exome libraries for the eight families were constructed using Agilent SureSelectXT Target Enrichment System according to Illumina Paired End Sequencing Protocol (Agilent Technologies, CA, USA). Capturing of whole exon was carried out according to the protocol of Agilent’s Sure Select Human All 1 UTRs 71 MB v4 kit. The flow cells were sequenced as paired-end 150 base pair reads on an Illumina HiSeq ×10 platform to a minimum depth of 50× targeted region coverage using TruSeq SBS sequencing kit version 3 and HiSeq data collection version 2.0.12.0 software (Illumina, Inc., San Diego, CA, USA).

The raw sequence reads we obtained were aligned to the human genome reference sequence (hg19) using Burrows–Wheeler Aligner (BWA) with standard parameters [10]. The BWA-aligned reads were statistically calculated using PICARD software to exclude polymerase chain reaction duplicates. Regional realignment and quality score recalibration were carried out using Genome Analysis Toolkit [11] with recommended parameters, which included local realignment of the sequences around InDels, base quality score recalibration, variant calling and variant quality score recalibration.

Variant detection in the eight TOF children by Sanger sequencing

BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) and ABI 3130 Genetic Analyzer were used to detect variants among the eight TOF children.

Ethics statement

Approval was obtained from local ethics committees of Henan Provincial People’s Hospital, Zhengzhou University People’s Hospital. Informed consents were provided to all the participants of this study.

Acknowledgments

The authors are grateful to the patients and families who participated in this research. Team members who supported the subject recruitment and sequencing are as follows: Yan-ze Li (CapitalBio Technology), Qian Zhang, Hao-ju Dong, Shu-bo Song, Yan-wei Zhang, Jia-yong Zheng, Feng Ai, Dan-qing Huang and Juan Zhang.

Abbreviations

TOF

tetralogy of Fallot

CHD

congenital heart disease

WES

whole-exome sequencing

SNPs

single nucleotide polymorphisms

CNVs

copy number variations

DNA

deoxyribonucleic acid

BWA

Burrows–Wheeler Aligner

GATK

Genome Analysis Toolkit

BTF3

basic transcription factor 3

NAC

nascent polypeptide-associated complex

SRP

signal recognition particle

Author contributions

Lin Liu designed the experiments, recruited patients, collected samples, analysed the data, performed statistics and wrote the manuscript. Hong-dan Wang designed the experiments, recruited the patients, collected samples, analysed the data, performed statistics and wrote the manuscript. Cun-ying Cui recruited the patients, collected the samples, analysed the data and wrote the manuscript. Yun-yun Qin collected samples, analysed the data and wrote the manuscript. Tai-bing Fan collected the samples. Bang-tian Peng collected the samples. Lian-zhong Zhang performed the statistics. Cheng-zeng Wang designed the experiments, recruited patients and critically reviewed the manuscript.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

FUNDING

This study was supported by National Natural Science Foundation of China (81401419), Program of Science and Technology of Henan Province (172102310003) and Program of Advanced Study to go Abroad of Henan Provincial Health System (2016047).

REFERENCES

  • 1.Bédard E, McCarthy KP, Dimopoulos K, Giannakoulas G, Gatzoulis MA, Ho SY. Structural abnormalities of the pulmonary trunk in tetralogy of Fallot and potential clinical implications: a morphological study. J Am Coll Cardiol. 2009;54:1883–90. doi: 10.1016/j.jacc.2009.06.040. [DOI] [PubMed] [Google Scholar]
  • 2.Beauchesne LM, Warnes CA, Connolly HM, Ammash NM, Grogan M, Jalal SM, Michels VV. Prevalence and clinical manifestations of 22q11.2 microdeletion in adults with selected conotruncal anomalies. J Am Coll Cardiol. 2005;45:595–98. doi: 10.1016/j.jacc.2004.10.056. [DOI] [PubMed] [Google Scholar]
  • 3.Goldmuntz E, Geiger E, Benson DW. NKX2.5 mutations in patients with tetralogy of Fallot. Circulation. 2001;104:2565–68. doi: 10.1161/hc4601.098427. [DOI] [PubMed] [Google Scholar]
  • 4.Salazar M, Consoli F, Villegas V, Caicedo V, Maddaloni V, Daniele P, Caianiello G, Pachón S, Nuñez F, Limongelli G, Pacileo G, Marino B, Bernal JE, et al. Search of somatic GATA4 and NKX2.5 gene mutations in sporadic septal heart defects. Eur J Med Genet. 2011;54:306–09. doi: 10.1016/j.ejmg.2011.01.004. [DOI] [PubMed] [Google Scholar]
  • 5.Eldadah ZA, Hamosh A, Biery NJ, Montgomery RA, Duke M, Elkins R, Dietz HC. Familial Tetralogy of Fallot caused by mutation in the jagged1 gene. Hum Mol Genet. 2001;10:163–69. doi: 10.1093/hmg/10.2.163. [DOI] [PubMed] [Google Scholar]
  • 6.Bauer RC, Laney AO, Smith R, Gerfen J, Morrissette JJ, Woyciechowski S, Garbarini J, Loomes KM, Krantz ID, Urban Z, Gelb BD, Goldmuntz E, Spinner NB. Jagged1 (JAG1) mutations in patients with tetralogy of Fallot or pulmonic stenosis. Hum Mutat. 2010;31:594–601. doi: 10.1002/humu.21231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Lu JH, Chung MY, Betau H, Chien HP, Lu JK. Molecular characterization of tetralogy of Fallot within Digeorge critical region of the chromosome 22. Pediatr Cardiol. 2001;22:279–84. doi: 10.1007/s002460010230. [DOI] [PubMed] [Google Scholar]
  • 8.Stoll C, Dott B, Alembik Y, Roth MP. Associated congenital anomalies among cases with Down syndrome. Eur J Med Genet. 2015;58:674–80. doi: 10.1016/j.ejmg.2015.11.003. [DOI] [PubMed] [Google Scholar]
  • 9.Ng SB, Turner EH, Robertson PD, Flygare SD, Bigham AW, Lee C, Shaffer T, Wong M, Bhattacharjee A, Eichler EE, Bamshad M, Nickerson DA, Shendure J. Targeted capture and massively parallel sequencing of 12 human exomes. Nature. 2009;461:272–76. doi: 10.1038/nature08250. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics. 2010;26:589–95. doi: 10.1093/bioinformatics/btp698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, Philippakis AA, del Angel G, Rivas MA, Hanna M, McKenna A, Fennell TJ, Kernytsky AM, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43:491–98. doi: 10.1038/ng.806. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Cuypers JA, Menting ME, Konings EE, Opić P, Utens EM, Helbing WA, Witsenburg M, van den Bosch AE, Ouhlous M, van Domburg RT, Rizopoulos D, Meijboom FJ, Boersma E, et al. Unnatural history of tetralogy of Fallot: prospective follow-up of 40 years after surgical correction. Circulation. 2014;130:1944–53. doi: 10.1161/CIRCULATIONAHA.114.009454. [DOI] [PubMed] [Google Scholar]
  • 13.Greenway SC, Pereira AC, Lin JC, DePalma SR, Israel SJ, Mesquita SM, Ergul E, Conta JH, Korn JM, McCarroll SA, Gorham JM, Gabriel S, Altshuler DM, et al. De novo copy number variants identify new genes and loci in isolated sporadic tetralogy of Fallot. Nat Genet. 2009;41:931–35. doi: 10.1038/ng.415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Bittel DC, Butler MG, Kibiryeva N, Marshall JA, Chen J, Lofland GK, O’Brien JE., Jr Gene expression in cardiac tissues from infants with idiopathic conotruncal defects. BMC Med Genomics. 2011;4:1–10. doi: 10.1186/1755-8794-4-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Sharma HS, Peters TH, Moorhouse MJ, van der Spek PJ, Bogers AJ. DNA microarray analysis for human congenital heart disease. Cell Biochem Biophys. 2006;44:1–9. doi: 10.1385/CBB:44:1:001. [DOI] [PubMed] [Google Scholar]
  • 16.Peters TH, Sharma V, Yilmaz E, Mooi WJ, Bogers AJ, Sharma HS. DNA microarray and quantitative analysis reveal enhanced myocardial VEGF expression with stunted angiogenesis in human tetralogy of Fallot. Cell Biochem Biophys. 2013;67:305–16. doi: 10.1007/s12013-013-9710-9. [DOI] [PubMed] [Google Scholar]
  • 17.Feiner L, Webber AL, Brown CB, Lu MM, Jia L, Feinstein P, Mombaerts P, Epstein JA, Raper JA. Targeted disruption of semaphorin 3C leads to persistent truncus arteriosus and aortic arch interruption. Development. 2001;128:3061–70. doi: 10.1242/dev.128.16.3061. [DOI] [PubMed] [Google Scholar]
  • 18.Brown CB, Feiner L, Lu MM, Li J, Ma X, Webber AL, Jia L, Raper JA, Epstein JA. PlexinA2 and semaphorin signaling during cardiac neural crest development. Development. 2001;128:3071–80. doi: 10.1242/dev.128.16.3071. [DOI] [PubMed] [Google Scholar]
  • 19.Amarillo IE, O’Connor S, Lee CK, Willing M, Wambach JA. De novo 9q gain in an infant with tetralogy of Fallot with absent pulmonary valve: patient report and review of congenital heart disease in 9q duplication syndrome. Am J Med Genet A. 2015;167A:2966–74. doi: 10.1002/ajmg.a.37296. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Grunert M, Dorn C, Schueler M, Dunkel I, Schlesinger J, Mebus S, Alexi-Meskishvili V, Perrot A, Wassilew K, Timmermann B, Hetzer R, Berger F, Sperling SR. Rare and private variations in neural crest, apoptosis and sarcomere genes define the polygenic background of isolated Tetralogy of Fallot. Hum Mol Genet. 2014;23:3115–28. doi: 10.1093/hmg/ddu021. [DOI] [PubMed] [Google Scholar]
  • 21.Huffnagel IC, Clur SA, Bams-Mengerink AM, Blom NA, Wanders RJ, Waterham HR, Poll-The BT. Rhizomelic chondrodysplasia punctata and cardiac pathology. J Med Genet. 2013;50:419–24. doi: 10.1136/jmedgenet-2013-101536. [DOI] [PubMed] [Google Scholar]
  • 22.Alazami AM, Patel N, Shamseldin HE, Anazi S, Al-Dosari MS, Alzahrani F, Hijazi H, Alshammari M, Aldahmesh MA, Salih MA, Faqeih E, Alhashem A, Bashiri FA, et al. Accelerating novel candidate gene discovery in neurogenetic disorders via whole-exome sequencing of prescreened multiplex consanguineous families. Cell Reports. 2015;10:148–61. doi: 10.1016/j.celrep.2014.12.015. [DOI] [PubMed] [Google Scholar]

Articles from Oncotarget are provided here courtesy of Impact Journals, LLC

RESOURCES